STRENSIQ 40 mg/mL (Asfotase Alfa SOLUTION) 40 mg/mL

STRENSIQ 40 mg/mL is a subcutaneous solution containing asfotase alfa, used for enzyme replacement therapy. This medication is designed to address specific metabolic conditions. Learn more about its uses and effects.

Strength

40 mg/mL

Pack Size

12 VIAL in 1 CARTON (25682-016-12) / 1 mL in 1 VIAL (25682-016-01)

Manufacturer / TM Owner

Alexion Pharmaceuticals, Inc.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

STRENSIQ 40 mg/mL is primarily used for enzyme replacement therapy. It is indicated for conditions related to metabolic disorders where enzyme deficiency is a factor. Patients often seek this treatment to manage symptoms associated with these disorders. The medication works by replacing the missing enzyme, helping to alleviate related symptoms.

Side Effects

Common effects of STRENSIQ 40 mg/mL may include reactions at the injection site, such as redness or swelling. Some users might experience mild discomfort or itching. These effects are generally temporary and subside over time. Always consult a healthcare provider for personalized advice.

Precautions & Warnings

STRENSIQ 40 mg/mL should be handled with care. It is important to follow proper storage and administration guidelines to ensure safety. Patients should be aware of potential allergic reactions and seek medical attention if severe symptoms occur. Always use this medication as directed by a healthcare professional.

Avoid Interactions

STRENSIQ 40 mg/mL may interact with other medications, including those that affect the immune system. It is advisable to inform your healthcare provider about all medications you are taking to avoid potential interactions. Alcohol and certain supplements might also influence the effectiveness of this treatment.

Frequently Asked Questions

STRENSIQ 40 mg/mL is used for enzyme replacement therapy in conditions related to metabolic disorders.

STRENSIQ 40 mg/mL is administered subcutaneously, typically by a healthcare professional or trained individual.

Common side effects may include reactions at the injection site, such as redness or swelling.

It is important to consult a healthcare provider before combining STRENSIQ 40 mg/mL with other medications.

STRENSIQ 40 mg/mL should be stored according to the manufacturer's guidelines to maintain its effectiveness.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.